The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 15, 2023
Filed:
Apr. 27, 2018
Applicants:
Baylor College of Medicine, Houston, TX (US);
The General Hospital Corporation, Boston, MA (US);
Inventors:
Gianpietro Dotti, Chapel Hill, NC (US);
Soldano Ferrone, Boston, MA (US);
Assignees:
The General Hospital Corporation, Boston, MA (US);
Baylor College of Medicine, Houston, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3076 (2013.01); A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/01 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01);
Abstract
Embodiments of the disclosure include methods and compositions related to chimeric antigen receptors (CAR) that target chondroitin sulfate proteoglycan-4 (CSPG4). T cells transduced with a CSPG4-specific CAR are effective for inhibition of particular cancer cells that express CSPG4. In certain embodiments, the cancer is melanoma, breast cancer, head and neck cancer, mesothelioma, glioblastoma, or renal cancer.